Putative BRAF activating fusion in a medullary thyroid cancer.
about
Somatic cancer variant curation and harmonization through consensus minimum variant level dataThe safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Whole exome sequencing identifies a germline MET mutation in two siblings with hereditary wild-type RET medullary thyroid cancer.
P2860
Putative BRAF activating fusion in a medullary thyroid cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Putative BRAF activating fusion in a medullary thyroid cancer.
@en
type
label
Putative BRAF activating fusion in a medullary thyroid cancer.
@en
prefLabel
Putative BRAF activating fusion in a medullary thyroid cancer.
@en
P2093
P2860
P50
P356
P1476
Putative BRAF activating fusion in a medullary thyroid cancer
@en
P2093
Blair A Walker
Jacqueline E Schein
Katayoon Kasaian
Martin Hirst
Richard A Moore
Sam M Wiseman
P2860
P304
P356
10.1101/MCS.A000729
P577
2016-03-01T00:00:00Z